Detalles de la búsqueda
1.
Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study.
Respirology
; 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38654512
2.
Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
Cancer Immunol Immunother
; 72(8): 2613-2621, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062033
3.
Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy.
J Thorac Oncol
; 19(2): 325-336, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37748690
4.
Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report.
JTO Clin Res Rep
; 5(4): 100657, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38706977
5.
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Lung Cancer
; 191: 107788, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38593478
6.
Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report.
Thorac Cancer
; 14(2): 206-209, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36453575
7.
Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Cancer Med
; 12(11): 12388-12401, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062059
8.
Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles.
Thorac Cancer
; 14(29): 2909-2923, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37614219
9.
Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.
Clin Lung Cancer
; 23(6): 477-486, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644780
10.
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
J Thorac Oncol
; 17(10): 1227-1232, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35788404
11.
Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
Lung Cancer
; 167: 49-57, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35397298
12.
CT Guided Needle Biopsy of Peripheral Lesions-Lesion Characteristics That May Increase the Diagnostic Yield and Reduce the Complication Rate.
J Clin Med
; 10(9)2021 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34065147
13.
Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Allergy Asthma Clin Immunol
; 16: 46, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32536947
14.
A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
J Thorac Oncol
; 19(2): 351-352, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325987
15.
Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses.
Cancer Commun (Lond)
; 44(2): 287-293, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37882647
Resultados
1 -
15
de 15
1
Próxima >
>>